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despite adequate treatment. About 30% of patients do not achieve remission after 4 
different antidepressant treatment trials (Rush et. Al., 2006). a few studies have 
examined the economic burden of TRD, but none have investigated the cost associated 
with more chronic and extensive forms of TRD characterized by non-response to four 
or more treatment trials. The objective of this study is to compare the direct medical 
expenditures of TRD patients to chronic MDD patients. METHODS: Patients with 
chronic MDD (deﬁ ned as 2 or more years of continuous treatment) and patients with 
very severe TRD (deﬁ ned as switching, augmentation, or addition of at least four 
qualifying therapies) were identiﬁ ed in the PharMetrics Patient-Centric Database. 
Medical resource utilization (MRU) and payer costs per patient per year enrolled in 
the plan were compared. Patients were matched on duration of enrollment, length of 
depression, medications taken, and age. Statistical signiﬁ cance was assessed using 
Student’s t-tests. RESULTS: The average medical expenditures per TRD (n = 31,803) 
patient per year enrolled was $12,260 compared to $7,619 for non-TRD chronic 
MDD patients (n = 50,092) (p < 0.001), representing 60.9% higher costs per year. 
The differences in annual medical expenditures per TRD patient were primarily driven 
by higher medical and pharmacy MRU (number of services per patient) relative to the 
chronic MDD group (70.3 vs. 107.6, p < 0.001). CONCLUSIONS: Our results dem-
onstrate that TRD patients accrued signiﬁ cantly higher per patient medical costs than 
MDD patients due to higher medical resource use. These ﬁ ndings suggest that more 
effective non-pharmacological alternative interventions are needed.
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OBJECTIVES: Data concerning impact and costs of hospitalization in patients with 
schizophrenia are scarce in Germany. Aim of this claims data analysis was to examine 
the impact and costs of hospitalization in schizophrenia from the perspective of a 
major statutory health insurance fund. METHODS: A nation-wide database was used 
to evaluate the impact and related costs of hospitalization in schizophrenia (ICD-10 
F20.x) between 2004 and 2006. All hospitalised patients were identiﬁ ed based on 
claims data and schizophrenia related costs for outpatient care, inpatient care, medica-
tions, rehabilitation, occupational therapy, and sick leave payments were analyzed 
before, during and after the hospitalization. RESULTS: Data from 4126 hospitalised 
patients were available, with 46% being female and a mean age of 42 years. Mean 
length of the index hospitalization was 45.9 days and mean health insurance costs of 
c9366 incurred during the index hospitalization. In the 3 months before the index 
hospitalization, average costs of c297 and in the 3 months after the index hospitaliza-
tion costs of c2322 incurred for outpatient care, inpatient care, medications, rehabili-
tation, occupational therapy, and sick leave payments. 42.5% of the patients had at 
least one rehospitalization after the index hospitalization and mean costs of c8710 
incurred during the ﬁ rst rehospitalization. In the 4 weeks before the ﬁ rst rehospitaliza-
tion average costs of c1310 and in the 3 months after the rehospitalization costs of 
c2834 incurred. With any further rehospitalization costs for the inpatient care itself 
are decreasing slightly but overall costs for schizophrenia related medical care before 
and after the event are increasing. CONCLUSIONS: Impact and costs of hospitaliza-
tion in schizophrenia are signiﬁ cant, especially if the costs before and after hospitaliza-
tion were taken into account. Rehospitalizations are a frequent event in schizophrenia 
care with high impact on costs. Further studies including the predictors of hospitaliza-
tion are needed.
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OBJECTIVES: To investigate the health care resource utilization and costs for Swedish 
bipolar disorder patients. METHODS: Registry data on socio-demographics and 
disease-related resource use during 2006–2008 was collected for 1846 patients with 
bipolar disorder. Health care visits and hospitalizations were obtained from the 
Northern Stockholm psychiatric clinic, while data on pharmaceuticals and sick leave 
were obtained from the national pharmaceutical registry and the Swedish social insur-
ance agency, respectively. Community care data was obtained from the Swedish 
quality registry for bipolar disorder (BipoläR). Indirect costs were valued according 
to the human capital method. Costs across mood episodes (manic, depressive, and 
unspeciﬁ ed) as well as remission were calculated. a patient for which >70 days had 
passed since the last new episode or inpatient visit, was deﬁ ned as being in remission. 
RESULTS: The mean annual cost per patient with bipolar disorder was estimated at 
c24,300 (SEK 242,810) in 2009 prices, of which 23% represented direct treatment 
costs. The costs per month for active bipolar disorder were c6800 during depression, 
c6300 during mania, EUR 6,100 during unspeciﬁ ed episodes, and c1500 for patients 
in remission. a patient who was not hospitalized during 2006–2008 generated a mean 
annual cost of c18,900, whereas a patient who was hospitalized at least once every 
year 2006–2008 generated mean annual costs of c67,600. CONCLUSIONS: Societal 
costs for bipolar disorder were more than 3.5 times higher for patients who were 
admitted at least once per year in 2006–2008 compared to those who were not hos-
pitalized. Monthly costs during a depressive or manic episode were more than 4 times 
higher than during remission. Attempts to prevent mood episodes by means of effective 
treatment may not only decrease patient suffering, but also have the potential to 
dramatically reduce the societal cost of illness.
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OBJECTIVES: Rising life expectancy is associated with increasing prevalence of 
dementia in European countries. With progressing disease severity patients’ call on 
health care services and social support grows. Several studies stress the burden 
imposed on family members caring for dementia-patients. However, empirical data 
assessing the economic value of informal care compared to health insurance expendi-
tures is scarce. Within the cluster-randomized IDA study health care service utilization 
and informal caregiving time were assessed for 383 community living individuals 
suffering from mild to moderate dementia. METHODS: To examine costs from a 
health insurance perspective administrative data on all types of services provided were 
collected and valued with corresponding administrative prices over a three-year 
period. Patients’ caregivers reported in yearly interviews the hours daily dedicated to 
the patient in care and supervision. The time provided for informal caregiving was 
valued by applying hourly wages of a nursing service and a domestic help respectively. 
Total costs and cost components were calculated from societal perspective and payers’ 
point of view and analyzed by relevant subgroups. RESULTS: Caring for a home-
dwelling dementia-patient amounts annually to around c47.000 from societal perspec-
tive with informal care covering nearly 80% of this sum. For a patient with moderate 
dementia values assigned to informal care are approximately 70% higher than for a 
person with mild dementia. Health insurance has to spend c10,000 for an average 
dementia-patient per year, with services for long-term care representing the most costly 
part. CONCLUSIONS: Informal care is the major cost component in care for demen-
tia, and it is strongly rising with disease progression. Changes in family structures and 
traditional living arrangements thus pose an enormous challenge regarding the future 
organization of dementia care. To maintain today’s care-setting, concepts fostering 
community-based dementia care and support to family caregivers need to be further 
developed.
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OBJECTIVES: Literature on the costs of community support programs is scant. Beat 
the Blues (BTB) is a home support program for depression which involves trained 
social workers who meet with participants to identify care management concerns, 
make referrals and linkages, provide depression education, develop tailored action 
plans to accomplish identiﬁ ed behavioral goals and enhance engagement in pleasurable 
activities, and teach stress reduction techniques for managing daily stressors (e.g., deep 
breathing). The primary objective of this study is to assess the cost of implementing 
BTB in African American elders with depressive symptoms. METHODS: The cost 
analysis is piggybacked onto the parent BTB trial, which employs randomized two-
group experimental design (treatment vs. control). Candidates are screened twice for 
depressive symptoms (PHQ-9 score > 5) to determine eligibility. Participants are 
randomly assigned to intervention or waitlist control. BTB is administered over 4 
months with assessments in both groups at baseline and 4-months. Cost components 
comprise 4 main categories (Screening, Intervention Delivery, Supervision, and Other). 
Senior center management and social workers (interventionists) kept detailed logs of 
time spent conducting each component. The cost of conducting the intervention was 
calculated as the time spent performing each task multiplied by wage rate of the 
individual who performed the task. Non-time related cost (material and mileage) was 
also calculated. RESULTS: A total of 166 participants received the intervention. 
Average cost of BTB was $342 per person. The most costly aspect of BTB per person 
was cost of program delivery ($275), followed by materials ($48).The least costly 
aspect of the intervention was time spent supervising interventionists ($9). CONCLU-
SIONS: This study informs decision makers about the resources required for depres-
sion community support interventions, which are not typically reimbursable through 
private or public health care programs. Results can also inform decision making 
regarding the costs of such interventions in relation to pharmacological treatments.
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OBJECTIVES: To analyze the health care utilization by patients diagnosed with major 
depressive disorder (MDD). METHODS: This was a retrospective longitudinal 
descriptive database study of the utilization of health care by patients with MDD from 
the South-West region of Sweden (1.5 million inhabitants). All patients who were 
diagnosed with MDD (ICD-10 F32 or F33) during 2007 were included in the study. 
All costs from health care visits when an MDD was the primary diagnose were 
included as well as all cost from all dispensed antidepressant (ATC N06A) drugs. 
RESULTS: A total of 37,445 patients had at least one health care visit with an MDD 
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diagnoses during 2007 in the South-West region of Sweden. Sixty-two percent of the 
patients had at least one visit to the primary care, 35% had been treated as out-patient, 
9% had been treated by private physician, and 7% had been treated by in-patient 
care; 73% had at least one dispensed drug. The total health care cost, including drug 
cost, was 683 million SEK. 35% were from drugs and 23%, 26%, 14%, and 1% were 
from in-patient, out-patient, primary, and private care. During 2007 the average drug 
cost per patient, who utilize the current treatment, was 8847 SEK for drugs. The 
average cost for in-patient care was 64,576 SEK and 13,859 SEK for out-patient care. 
For primary and private care the average cost was 4268 SEK and 1342 SEK. CON-
CLUSIONS: The cost for antidepressant drugs was the largest part of the total health 
care cost for MDD, 35%. The in-patient care was the greatest cost per patient. The 
relevant question is what mix of drugs should be prescribed in order to minimize the 
total health care cost. Further research needs to be preformed.
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OBJECTIVES: Population based study to determine clinical consequences and eco-
nomic impact of using escitalopram (ESC) vs. citalopram (CIT) and venlafaxine (VEN) 
in patients initiating treatment for a new episode of major depression (MD), in real-life 
conditions of outpatient practice. METHODS: Observational, multicenter, retrospec-
tive study conducted using computerized medical records (administrative databases) 
of patients treated in six primary care centers and two hospitals between January 2003 
and March 2007. Study population: patients >20 years of age diagnosed with a new 
episode of MD who initiate treatment with ESC, CIT or VEN, and whithout any 
antidepressant treatment within the previous 6 months, who were followed for 18 
months or more. Main variables: socio-demographic variables, remission, comorbid-
ity, annual health care costs (medical visits, diagnostic and therapeutic tests, hospital-
izations, emergency room and psychoactive drugs prescribed) and non-health care 
costs (productivity loss at work). Statistical analyses: logistic regression and ANCOVA 
models. RESULTS: A total of 965 patients (ESC = 131; CIT = 491; VEN = 343) were 
included. ESC-treated patients were younger, with a higher proportion of males, and 
a lower speciﬁ c comorbidity (P < 0.01). ESC-treated patients achieved higher remission 
rates (58.0%) compared to CIT (38.3%) or VEN (32.4%) patients (P < 0.001) and 
had lower productivity work ESC (37.9 days) vs.CIT (32.7 days) or vs. VEN (43.8 
days), p = 0.042. No differences in average/unit costs of psychoactive drugs were 
observed between the ESC and CIT groups (c294.7 vs. c265.2), with higher costs seen 
in the VEN group (c643.0), p = 0.003. In the corrected model, total (health care and 
non-health care) costs were lower with ESC (c2276.2) vs. CIT (c3093.8), p = 0.047 
and VEN (c3801.2), p = 0.045. CONCLUSIONS: ESC appears to be dominant in the 
treatment of new MD episodes when compared to CIT and VEN, resulting in higher 
remission rates and lower total costs.
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OBJECTIVES: To analyze the cost of MMT treatment for patient with substance use 
disorder. METHODS: This was a retrospective study involving 185 opiate dependence 
patients who were receiving MMT treatment program in Malaysian’s government 
hospitals starting December 2005 until February 2010. The study was done from the 
provider perspective using activity based costing that includes both capital and vari-
able cost associated with MMT program. RESULTS: Most of the respondents were 
male (99%) with mean age of 38.5 years. Most (72.5%) of them were Malay and 
50.5% working in semi or unskilled manual job with basic salary less than MYR1000 
(US$312). Most (99.5%) were smoker with history of heroin addiction of more than 
10 years. The median length of MMT treatment was 14 months. Fifty-seven percent 
of the patients were suffering from chronic disease. The capital cost for MMT program 
was US$8013.16 and the variable cost of providing a month of treatment per patient 
was US$50.43. Approximately 47.19% of this was for methadone and personnel cost 
accounted for 31.94%. The variable cost was statistically higher (P < 0.05) in patients 
present of chronic disease. CONCLUSIONS: This study estimated the variable cost 
of MMT treatment per patient in Malaysia (US$50.43/month) is less expensive 
compare USA (US$220/month, Jones et al., 2009). These cost data may be useful to 
policymakers and researchers for further developing the program.
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OBJECTIVES: To describe new data on recent trends in U.S. psychiatric prescription 
drug spending and utilization over the period 2003 to 2008 and to understand drivers 
of those new trends. METHODS: SAMSA Spending Estimates were coupled with 
MEPS data to examine trends in mental health drug spending and utilization through 
2005. 1997–2008 Thomson Reuters MarketScan Commercial Claims data were used 
to decompose spending where: Total Expenditures = Price X Quantity, and ΔCost/
Enrollee = ΔCost/Day X ΔDays/User X ΔUsers/Enrollees. The following drugs were 
included in the analysis: Antidepressants, Antipsychotics, Stimulants, and Anxiolytic/
Sedative/Hypnotics. RESULTS: The average annual growth rate in mental health 
prescription drug spending dropped from 28% in 1998 to 3% in 2008. The rate of 
growth has stayed below 10% since 2005, and was negative in 2007. For persons 
with private insurance, the average annual expenditure growth rate overall was 6% 
during the years 2001–2008, where 2% was attributable to days/user, 2% was due 
to users per population, and 2% was due to cost/day. In contrast for the years 
1997–2001, the average growth rate overall was 18%, where 3% was attributable to 
days/user, 7% was due to users per population, and 8% was due to cost/day. 
CONCLUSIONS: Mental health prescription drug spending growth has slowed in 
recent years. This is due primarily to slower growth in additional users and slower 
price growth. The lower price growth is mainly due to generic entries starting in 2005, 
particularly within the antidepressant drug class.
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OBJECTIVES: To analyze the clinical and economic effects of the use of Pregabalin 
(PGB) in patients with refractory severe Generalized Anxiety Disorder (GAD) and 
severe concomitant depressive symptoms in daily medical practice. METHODS: Data 
were obtained from a post-hoc analysis of a 6-month, prospective, non-interventional 
study conducted in outpatient psychiatric clinics to ascertain the impact of broadening 
GAD diagnostic criteria. This before-after study included PGB naïve patients above 
18 years, with GAD (using DSM-IV criteria), refractory to anxiolytics for a minimum 
of 3 months, severe symptoms of anxiety (HAM-A > 24) and depression (MADRS > 
35), who received ﬂ exible doses of PGB either as monotherapy or add-on, per psy-
chiatrist judgment. Changes in HAM-A and MADRS and responders rates (reduction 
> 50% of baseline scoring) were the study end-points, together with health care 
resources utilization and corresponding costs. RESULTS: A total of 159 patients 
[69.2% women, mean age 45.9 (12.6) years] fulﬁ lled criteria for analysis. Ninety 
percent or more patients were previously exposed to benzodiazepines and/or antide-
pressants [mean 2.7 (1.3) drugs]. Adding PGB [mean dose: 223.1 (126.3) mg/day] 
reduced both anxiety and depressive symptoms, respectively, in HAM-A and MADRS 
scales, by −57.9% (from 35.5 + 5.8 to 14.8 + 9.4; P < 0.001, effect size: 3.57) and 
−58.1% (from 39.4 + 4.3 to 16.5 + 10.3; P < 0.001, effect size: 5.33). As a result, 
responder rates were 63.1% and 62.9%, respectively. Costs reductions in medical 
visits [−c1022 (−1,376; −669), P < 0.001] and hospitalizations [−c144 (−245;−44), p 
= 0.005], offset the higher incremental drug cost of PGB treatment [c353 (292; 415), 
P < 0.001] showing statistically reduction of health care costs; −c619 (−1,040;−197), 
p = 0.004. CONCLUSIONS: The use of Pregabalin resulted in both clinical and 
economic beneﬁ ts in patients with severe refractory GAD and concomitant severe 
depressive disorder. Patients experienced a signiﬁ cant improvement in their anxiety 
and depression symptoms, improvements which were associated with signiﬁ cant 
decreases in health care costs.
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OBJECTIVES: Patients with schizophrenia experience elevated rates of morbidity and 
mortality, largely due to an increased incidence of cardiovascular disease and diabetes. 
The STAR study showed that the metabolic side effects of aripiprazole treatment are 
less than that experienced by those receiving standard-of-care (SOC) antipsychotic 
treatment (olanzapine, queatipine or risperidone). This study estimates the difference 
in direct and indirect cost-consequences of diabetes and coronary heart disease (CHD) 
in schizophrenia patients treated with aripiprazole or SOC. METHODS: On the basis 
of the results provided by the STAR study, risks for diabetes and CHD were projected 
over a time horizon of 10 years in the Spanish setting using the Stern and Framingham 
models. The comparators were aripiprazole versus SOC. The prevalence and costs 
(direct and indirect) of diabetes and CHD were obtained from Spanish sources. All 
costs were inﬂ ated to 2009 costs using the Spanish Health System pay and prices 
index. RESULTS: The number of avoided diabetes cases (23.4 cases per 1,000 treated 
patients) in patients treated with aripiprazole compared to SOC was associated with 
estimated total (direct and indirect) cost saving of c27,798,018 over 10 years for the 
Spanish population. Similarly, with aripiprazole the number of avoided CHD events 
(3.7 events per 1,000 treated patients) yields an estimated total cost saving of 
c4,173,818 over 10 years. CONCLUSIONS: Compared with SOC, aripiprazole 
